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Unmet needs of diabetic patientsDiabetes mellitus is a major risk factor for coronary heart
disease. According to the National Cholesterol Education
Program (NCEP) and Adult Treatment Panel III (ATPIII)
recommendations, diabetes can be considered to be equivalent
to coronary heart disease.1 In the United Kingdom Prospective
Diabetes Study (UKPDS), low-density-lipoprotein cholesterol
(LDL-C) is the most important risk factor for coronary heart
disease in diabetes.2 A meta-analysis of 14 statin trials (which
included 18,686 diabetic participants) showed that with an
average 39 mg/dL reduction in LDL-C over 4.3 years, all-
cause mortality was decreased by 9% and major cardiovas-
cular events by 21%.3 These results suggest that statins have
become the most important medication for decreasing
cardiovascular events in patients with diabetes, especially
those who also suffer from coronary heart disease. The clinical
practice recommendation from the American Diabetes Asso-
ciation suggests that statin therapy should be added to lifestyle
therapy, regardless of baseline lipid levels, for diabetic patients
with overt cardiovascular disease.4 The treatment target for
LDL-C for such patients is <70 mg/dL.5
Clinical trial results indicate that patients with high tri-
acylglycerol levels cannot be effectively treated with fibrates
to reduce cardiovascular outcomes. In the Fenofibrate Inter-
vention and Event Lowering in Diabetes (FIELD) study, the
use of fenofibrate did not significantly change the primary end-
point of nonfatal myocardial infarction or death related to
coronary heart disease.6 Similarly, in the Action to Control
CardiOvascular Risk in Diabetes (ACCORD) trial, the addi-
tion of fenofibrate to simvastatin vs. simvastatin plus placebo
did not reduce the risk of cardiovascular events.7 Therefore,
fibrate therapy was not strongly recommended as a clinical
practice tool by the American Diabetes Association.4
Regarding antiplatelet therapy, the American Diabetes Asso-
ciation has recommended aspirin therapy (75e162 mg/d) as
a primary strategy in those patients with type 1 or type 2
diabetes who are at increased cardiovascular risk (10-year risk
>10%), and as a secondary prevention strategy in those with
diabetes and a history of cardiovascular disease.4
Despite tremendous evidence supporting the efficacyof these
evidence-based therapies, including statin and aspirin therapy,
their utilization has been suboptimal in daily practice. For
instance, in the recent CEPHEUS Pan-Asian survey (2012), the
goal attainment for LDL-C was only 34.9% (70 mg/dL) in
patients with a very high cardiovascular risk, which included1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2012.08.016patients with concomitant diabetes and coronary heart disease.8
In the Return on Expenditure Achieved for Lipid Therapy in
Asia (REALITY-Asia, 2008) survey, which enrolled 2622
patients in six Asian countries, the overall rate of attainment of
the target (LDL-C < 100 mg/dL) for patients with diabetes and
coronary heart disease was only 38%.9 Furthermore, the goal
attainment rate was only 16% for these patients in Taiwan, the
lowest among all six countries involved in the REALITY-Asia
survey. The frequency of use of aspirin in patients with dia-
betes and coronary heart diseasewas reported to be substantially
reduced in Asian countries.
In the current issue of the Journal of the Chinese Medical
Association, Yi-Chun Lin et al report on the utilization of statins
and aspirin among patients with diabetes and hyperlipidemia in
Taiwan.10 The authors used information culled from the Taiwan
National Health Insurance Database, and analyzed the
prescription of statins and aspirin in two calendar periods: period
1 (September 1998 to June 2002) and period 2 (July 2002 toApril
2006). They found an increase in the prescription of statins and
aspirin in period 2 compared with period 1. However, the
prescription rates were suboptimal in both periods. For patients
with the highest risk (diabetes plus coronary heart disease), the
prescription of statins increased from 30.3% (period 1) to 42.6%
(period 2); the prescription of aspirin increased from 43.5%
(period 1) to 52.5% (period 2). In contrast, the prescription rate of
fibrates decreased from 15.3% (period 1) to 11.7% (period 2).
Only 25.9% of patients received both statins and aspirin. The
decrease in utilization in fibrate is expected, due to the failure of
fibrate use to show any tangible benefit in the FIELD and the
ACCORD trials.6, 7 The major limitation of this study is that the
level of LDL-C for each patient was unknown, and the rate of
attainment of the goal could not be ascertained. Interestingly,
there was a decrease in the use of these medications in the year
2002e2003, probably due to the implementation of the Global
Budget Program in Taiwan in 2002.
In conclusion, the authors should be congratulated for their
important findings regarding unmet needs in diabetes
management in Taiwan, especially for those patients with
concomitant coronary heart disease. These patients have the
highest cardiovascular risk, yet they may be the group of
patients who can most cost-effectively benefit from optimal
medical therapy, which includes statins and aspirin. The health
authority and medical society should work together to improve
this grave condition.hinese Medical Association. All rights reserved.
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